http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/mxbbb-issues-voluntary-nationwide-recall-umary-acid-hyaluronic-due-presence-diclofenac-and

FDA Roundup: November 19, 2024
http://www.fda.gov/news-events/press-announcements/fda-roundup-november-19-2024

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/endo-expands-voluntary-recall-clonazepam-orally-disintegrating-tablets-usp-c-iv-due-potential

http://www.fda.gov/medical-devices/medical-device-recalls/battery-pack-correction-smiths-medical-updates-use-instructions-cadd-solis-li-ion-rechargeable

http://www.fda.gov/medical-devices/medical-device-recalls/ventilator-correction-philips-updates-use-instructions-trilogy-evo-evoo2-ev300-evo-universal-aeris

FDA Roundup: November 15, 2024
http://www.fda.gov/news-events/press-announcements/fda-roundup-november-15-2024

http://www.fda.gov/medical-devices/medical-device-recalls/endoscopic-vessel-harvesting-system-recall-getinge-and-maquet-cardiovascular-remove-vasoview-hemopro

FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency
http://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treatment-aromatic-l-amino-acid-decarboxylase-deficiency

FDA Roundup: November 8, 2024
http://www.fda.gov/news-events/press-announcements/fda-roundup-november-8-2024

FDA Proposes Ending Use of Oral Phenylephrine as OTC Monograph Nasal Decongestant Active Ingredient After Extensive Review
http://www.fda.gov/news-events/press-announcements/fda-proposes-ending-use-oral-phenylephrine-otc-monograph-nasal-decongestant-active-ingredient-after